Expert Interview
Reviewing EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Ticker(s): EDIT, VRTX, BLUE, CRSPInstitution: Howard University
- Professor of Medicine and Microbiology/Immunology & Director or the Center for Sickle Cell Disease at Howard University (previously held positions at the NIH and Johns Hopkins).
- Manages 355 patients with Sickle Cell Disease, 2 active Beta-Thalassemia patients and 1 HbH disease patient.
- Research interests include the use of genetic tools to understand and treat sickle cell disease and complications of transfusion therapy.
Please describe your background and clinical setting
Added By: ben_adminHow many patients with sickle cell disease do you manage?
Added By: ben_adminWhat is the current standard of care for sickle cell disease?
Added By: ben_adminHow well managed are patients with sickle cell disease?
Added By: ben_adminWhat are you overall thoughts on the potential of EDIT-301?
Added By: ben_adminWhat were your impressions of the recent data readout from the RUBY clinical trial?
Added By: ben_adminWhere would EDIT-301 fit into your treatment algorithm if it was approved?
Added By: ben_adminCan you rank your excitement for EDIT-301 on a scale of 1-10?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
